ScholarLens Back to search
1979•JAMARequires access

Toxicity of Penicillamine

John A. Goldman

Open publisher page 2 citations

Abstract

To the Editor.— The article by Halverson and associates (240:1870, 1978) regarding the toxicity of penicillamine omits one important factor of toxicity, that is, the dose the patient was receiving. This is one of the reasons that newer protocols for the administration of penicillamine stress the lower and slower dose schedules. It may well be that if the toxicity is dose related, and most rheumatologists are not using the highest doses that this group did, then the side effects stressed in this article are not pertinent to the present-day practice of using penicillamine for rheumatoid arthritis.

About this research paper

What this paper is about

To the Editor.— The article by Halverson and associates (240:1870, 1978) regarding the toxicity of penicillamine omits one important factor of toxicity, that is, the dose the patient was receiving. This is one of the reasons that newer protocols for the administration of penicillamine stress the lower and slower dose schedules. It may well be that if the toxicity is dose related, and most rheumatologists are not using the highest doses that this group did, then the side effects stressed in this article are not pertinent to the present-day practice of using penicillamine for rheumatoid arthritis.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To the Editor.— The article by Halverson and associates (240:1870, 1978) regarding the toxicity of penicillamine omits one important factor of toxicity, that is, the dose the patient was receiving. This is one of the reasons that newer protocols for the administration of penicillamine stress the lower and slower dose schedules. It may well be that if the toxicity is dose related, and most rheumatologists are not using the highest doses that this group did, then the side effects stressed in this article are not pertinent to the present-day practice of using penicillamine for rheumatoid arthritis.

Key concepts: Medicine, Penicillamine, Toxicity, Pharmacology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Toxicity of Penicillamine — Research Paper | ScholarLens